# Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

> **NCT06472388** · PHASE2 · RECRUITING · sponsor: **AC Camargo Cancer Center** · enrollment: 100 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Progression
- Neuroendocrine Tumor Grade 1
- Neuroendocrine Tumor Grade 2
- Neuroendocrine Tumor of Pancreas
- Neuroendocrine Tumor of the Lung
- Neuroendocrine Tumor Carcinoid

## Interventions

- **DRUG:** Everolimus 5 MG

## Key facts

- **NCT ID:** NCT06472388
- **Lead sponsor:** AC Camargo Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-24
- **Primary completion:** 2026-05-20
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06472388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06472388, "Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06472388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*